Other News

ACORAI Presents Positive Results in 1,600-Patient CAPTURE-HF Study for its AI-Powered Non-Invasive Multi-Sensor Platform for Improved Heart Failure Patient Management

MINNEAPOLIS, Oct. 6, 2025 /PRNewswire/ — Acorai, a clinical-stage company pioneering non-invasive hemodynamic monitoring for heart failure management, this week announced topline results from the 1,600-patient CAPTURE-HF study (Machine-Learning Estimation of Pulmonary Capillary Wedge and…

Remedy Robotics Debuts Pioneering Endovascular Surgical Robotic System and Completes World’s First Fully Remote Neurointerventional Procedures

Groundbreaking remotely operable robotic system to transform intervention for stroke and cardiovascular disease, while radically expanding access to care for patients around the world. SAN FRANCISCO, Oct. 6, 2025 /PRNewswire/ — Remedy Robotics, Inc., a leading medical technology company,…

Medtronic receives CE Mark for Penditure™ Left Atrial Appendage (LAA) Exclusion System, ushering in a new era of left atrial appendage management in Europe as it surpasses 10,000 Penditure Devices Sold Globally

Medtronic plc, a global leader in healthcare technology, today announced its Penditure™ Left Atrial Appendage (LAA) Exclusion System has officially received CE Mark approval and will be launched in Europe at the 39th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting from October 8-11 in Copenhagen, Denmark. The Penditure device recently […]

Positron Corporation Enters Industry Partnership Agreement with MedAxiom

Buffalo, NY, Oct. 02, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging technology company specializing in PET and PET-CT imaging systems and clinical services is pleased to announce a partnership with MedAxiom, the cardiovascular community’s premier source for organizational performance solutions. 

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK9 Inhibitor to Demonstrate Significant Reduction of Cardiovascular Events as Both Primary…

Groundbreaking Therapy for Advanced Heart Failure: Repairon Completes Series A Financing to Expand the Clinical Development of Its Regenerative Heart Therapy

GÖTTINGEN, Germany, Oct. 2, 2025 /PRNewswire/ — German biotech company Repairon GmbH announced the completion of a Series A round of financing that will enable further clinical development of its groundbreaking regenerative heart failure therapy. The therapy repairs cardiac function and…